modelN03AX09

Diagram of N03AX09

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Lamotrigine
ATC code:N03AX09
route:oral
compartments:1
dosage:100mg
volume of distribution:1.36L
clearance:39mL/min
other parameters in model implementation

Lamotrigine is an anticonvulsant medication primarily used to treat epilepsy and bipolar disorder. It is approved for the prevention and control of seizures and for the maintenance treatment of bipolar I disorder. Lamotrigine stabilizes neuronal membranes by inhibiting voltage-sensitive sodium channels.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects, both male and female, following oral administration of lamotrigine.

References

  1. Chan, V, et al., & Tett, SE (2001). Population pharmacokinetics of lamotrigine. Therapeutic drug monitoring 23(6) 630–635. DOI:10.1097/00007691-200112000-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11802095

  2. Yang, H, et al., & Mei, S (2024). Population Pharmacokinetics of Lamotrigine and Its N2-Glucuronide Metabolite in Chinese Patients With Epilepsy. Therapeutic drug monitoring 46(5) 649–657. DOI:10.1097/FTD.0000000000001207 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38666475

  3. Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)